Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Depressive symptoms and short telomere length are associated with increased mortality in bladder cancer patients.

Lin J, Blalock JA, Chen M, Ye Y, Gu J, Cohen L, Cinciripini PM, Wu X.

Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):336-43. doi: 10.1158/1055-9965.EPI-14-0992. Epub 2014 Nov 21.

2.

A review of cancer risk prediction models with genetic variants.

Wang X, Oldani MJ, Zhao X, Huang X, Qian D.

Cancer Inform. 2014 Sep 21;13(Suppl 2):19-28. doi: 10.4137/CIN.S13788. eCollection 2014. Review.

3.

γ-H2AX level in peripheral blood lymphocytes as a risk predictor for bladder cancer.

Fernández MI, Gong Y, Ye Y, Lin J, Chang DW, Kamat AM, Wu X.

Carcinogenesis. 2013 Nov;34(11):2543-7. doi: 10.1093/carcin/bgt270. Epub 2013 Aug 14.

4.

Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk.

Wang J, Wu X, Kamat A, Barton Grossman H, Dinney CP, Lin J.

Br J Cancer. 2013 Jun 11;108(11):2372-80. doi: 10.1038/bjc.2013.190. Epub 2013 Apr 30.

5.

Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy.

Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, Critelli R, Russo A, Andrew AS, Ye Y, Wu X, Kiemeney LA, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Vineis P, Matullo G.

Int J Cancer. 2013 Oct 15;133(8):2004-9. doi: 10.1002/ijc.28186. Epub 2013 Apr 25.

6.

Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer.

Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, Jacobs EJ, Malats N, De Vivo I, Albanes D, Purdue MP, Sharma S, Fu YP, Kogevinas M, Wang Z, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Gapstur SM, Thun M, Diver WR, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Hutchinson A, Burdett L, Jacobs KB, Yeager M, Fraumeni JF Jr, Chanock SJ, Silverman DT, Chatterjee N.

Cancer Res. 2013 Apr 1;73(7):2211-20. doi: 10.1158/0008-5472.CAN-12-2388. Epub 2013 Mar 27.

7.

A clinical risk prediction model for Barrett esophagus.

Thrift AP, Kendall BJ, Pandeya N, Vaughan TL, Whiteman DC; Study of Digestive Health.

Cancer Prev Res (Phila). 2012 Sep;5(9):1115-23. Epub 2012 Jul 11.

8.

Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers.

Park JH, Gail MH, Greene MH, Chatterjee N.

J Clin Oncol. 2012 Jun 10;30(17):2157-62. doi: 10.1200/JCO.2011.40.1943. Epub 2012 May 14.

9.

Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk.

Lin J, Forman MR, Wang J, Grossman HB, Chen M, Dinney CP, Hawk ET, Wu X.

Int J Cancer. 2012 Oct 15;131(8):1892-903. doi: 10.1002/ijc.27437. Epub 2012 Mar 6.

10.
11.

Rationale for an early detection program for bladder cancer.

Khochikar MV.

Indian J Urol. 2011 Apr;27(2):218-25. doi: 10.4103/0970-1591.82841.

12.

Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer.

Xing J, Dinney CP, Shete S, Huang M, Hildebrandt MA, Chen Z, Gu J.

Cancer. 2012 Jan 1;118(1):205-15. doi: 10.1002/cncr.26224. Epub 2011 Jun 20.

13.

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.

Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.

Eur J Epidemiol. 2011 Apr;26(4):313-37. doi: 10.1007/s10654-011-9551-z.

14.

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.

Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.

Eur J Hum Genet. 2011 May;19(5):18 p preceding 494. doi: 10.1038/ejhg.2011.27.

15.

DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer.

Marsit CJ, Koestler DC, Christensen BC, Karagas MR, Houseman EA, Kelsey KT.

J Clin Oncol. 2011 Mar 20;29(9):1133-9. doi: 10.1200/JCO.2010.31.3577. Epub 2011 Feb 22.

16.

Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk.

Liu Y, Shete S, Wang LE, El-Zein R, Etzel CJ, Liang FW, Armstrong G, Tsavachidis S, Gilbert MR, Aldape KD, Xing J, Wu X, Wei Q, Bondy ML.

Carcinogenesis. 2010 Oct;31(10):1762-9. doi: 10.1093/carcin/bgq141. Epub 2010 Jul 7.

17.

Comparison of discriminatory power and accuracy of three lung cancer risk models.

D'Amelio AM Jr, Cassidy A, Asomaning K, Raji OY, Duffy SW, Field JK, Spitz MR, Christiani D, Etzel CJ.

Br J Cancer. 2010 Jul 27;103(3):423-9. doi: 10.1038/sj.bjc.6605759. Epub 2010 Jun 29.

18.

Risk of urinary bladder cancer: a case-control analysis of industry and occupation.

Cassidy A, Wang W, Wu X, Lin J.

BMC Cancer. 2009 Dec 15;9:443. doi: 10.1186/1471-2407-9-443.

19.

Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer.

Stern MC, Lin J, Figueroa JD, Kelsey KT, Kiltie AE, Yuan JM, Matullo G, Fletcher T, Benhamou S, Taylor JA, Placidi D, Zhang ZF, Steineck G, Rothman N, Kogevinas M, Silverman D, Malats N, Chanock S, Wu X, Karagas MR, Andrew AS, Nelson HH, Bishop DT, Sak SC, Choudhury A, Barrett JH, Elliot F, Corral R, Joshi AD, Gago-Dominguez M, Cortessis VK, Xiang YB, Gao YT, Vineis P, Sacerdote C, Guarrera S, Polidoro S, Allione A, Gurzau E, Koppova K, Kumar R, Rudnai P, Porru S, Carta A, Campagna M, Arici C, Park SS, Garcia-Closas M; International Consortium of Bladder Cancer.

Cancer Res. 2009 Sep 1;69(17):6857-64. doi: 10.1158/0008-5472.CAN-09-1091. Epub 2009 Aug 25.

20.

Pharmacogenomics of platinum-based chemotherapy in NSCLC.

Hildebrandt MA, Gu J, Wu X.

Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):745-55. doi: 10.1517/17425250902973711. Review.

Items per page

Supplemental Content

Write to the Help Desk